Jiemiao Hu, Ph.D.
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Pediatrics – Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2013 | University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, US, Ph.D. in Biomedical Sciences |
| 2007 | Peking Union Medical College, Beijing, CN, M.S. in Biochemistry and Molecular Biology |
| 2004 | Peking University, Beijing, CN, BS in Chemistry |
Postgraduate Training
| 2013-2018 | Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Pediatrics – Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2021
Editorial Activities
Editorial Board member, Frontiers in Immunology, 2024 - Present
Honors & Awards
| 2018 | Scholarship, Keystone Symposia Conference Cancer Immunotherapy (C5) |
| 2012 - Present | Travel Award |
| 2011 - Present | Travel Award, University of Texas Graduate School of the Biomedical Sciences |
| 2006 - 2007 | Merit student, Peking Union Medical College |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2022. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. Conference. 105th American Association of Immunologists annual meeting IMMUNOLOGY2022. Portland, OR, US.
- 2020. CRS free T cell therapy: T cell membrane anchored and tumor targeted IL12 (ATTIL12)-T cell therapy eliminates large tumors, overcomes heterogeneity, and avoids adverse effects. Conference. IMMUNOLOGY2020. Honolulu, HI, US.
- 2016. CXCL9, CXCL10 and IFNγ favor the accumulation of infused T cells in tumors following IL-12 plus doxorubicin treatment. Conference. 100th American Association of Immunologists annual meeting IMMUNOLOGY2016. Seattle, WA, US.
International Presentations
- 2018. Combinational Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors. Conference. Keystone Symposia Cancer Immunotherapy (C5). Montreal, CA.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | MD Anderson Sarcoma SPORE |
| Funding Source: | NIH SPORE |
| Role: | Co-I |
| Date: | 2025 - 2028 |
| Title: | Novel Therapies for Osteosarcoma |
| Funding Source: | CPRIT MIRA |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proc Natl Acad Sci U S A 122(41):e2507542122, 2025. e-Pub 2025. PMID: 41052334.
- Hu, J, Lazar, A, Ingram, D, Wang, W, Zhang, W, Jia, Z, Ragoonanan, D, Wang, J, Xia, X, Mahadeo, KM, Gorlick, R, Li, S. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer 12(1), 2024. e-Pub 2024. PMID: 38199607.
- Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes NW, Yan J, Xia X, Yi SF, Dao LH, Masopust D, Heimberger AB, Li S. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun 14(1):735, 2023. e-Pub 2023. PMID: 36759517.
- Dao L, Zhao Q, Hu J, Xia X, Yang Q, Li S. A microfluidics-based method for isolation and visualization of cells based on receptor-ligand interactions. PLoS One 17(10):e0274601, 2022. e-Pub 2022. PMID: 36201506.
- Yang Q*, Hu J*, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Membrane-anchored and tumor-targeted IL-12 (attIL12)-PBMC therapy for osteosarcoma. Clin Cancer Res 28(17):3862-3873, 2022. e-Pub 2022. PMID: 35727602.
- Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Wall FN, Zhang Z, Mahadeo KM, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35027427.
- Wu M, Xia X, Hu J, Fowlkes NW, Li S. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nat Commun 12(1):3500, 2021. e-Pub 2021. PMID: 34108491.
- Hu J, Xia X, Zhao Q, Li S. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance. Cancer Lett 502:143-153, 2021. e-Pub 2021. PMID: 33279621.
- Hu J, Zhao Q, Kong LY, Wang J, Yan J, Xia X, Jia Z, Heimberger AB, Li S. Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv 7(5), 2021. e-Pub 2021. PMID: 33571109.
- Hu J, Xia X, Gorlick R, Li S. Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. Oncogene 38(49):7433-7446, 2019. e-Pub 2019. PMID: 31427736.
- Zhao Q*, Hu J*, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer 7(1):154, 2019. e-Pub 2019. PMID: 31208461.
- Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. Clin Cancer Res 24(12):2920-2934, 2018. e-Pub 2018. PMID: 29391351.
- Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunol Res 5(4):300-311, 2017. e-Pub 2017. PMID: 28223282.
- Hu J, Batth IS, Xia X, Li S. Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. Oncoimmunology 5(12):e1252012, 2016. e-Pub 2016. PMID: 28123894.
- Satelli A, Hu J, Xia X, Li S. Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells. J Cancer 7(13):1824-1832, 2016. e-Pub 2016. PMID: 27698922.
- Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, Gagea M, Mishra L, Li S. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol 64(5):1128-1136, 2016. e-Pub 2016. PMID: 26767500.
- Yan J, Kong LY, Hu J, Gabrusiewicz KR, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst 107(8), 2015. e-Pub 2015. PMID: 25971300.
- Noh H*, Hu J*, Wang X*, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 13(1):14, 2015. e-Pub 2015. PMID: 25889536.
- Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer 13(1):34, 2014. e-Pub 2014. PMID: 24565056.
- Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biol Proced Online 16(1):3, 2014. e-Pub 2014. PMID: 24495546.
- Flanagan, M, Gimble, JM, Yu, G, Wu, X, Xia, X, Hu, J, Yao, S, Li, S. Competitive electroporation formulation for cell therapy. Cancer Gene Ther 18(8):579-586, 2011. e-Pub 2011. PMID: 21660061.
- Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J, Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. PLoS One 6(8):e23270, 2011. e-Pub 2011. PMID: 21853100.
- Liu D, Yuan G, Hu J. Synthesis and photo-induced DNA cleaving activities of conjugates of halophenyl derivative and polyamide containing N-methylimidazoles. J Photochem Photobiol B 83(3):187-193, 2006. e-Pub 2006. PMID: 16403643.
Invited Articles
- Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol 35(4):325-339, 2016. e-Pub 2016. PMID: 25259408.
Other Articles
- Hu J, Liu X, Huang Q, Zhang B, Hughes D, Chandra J, Xia X, Li S Herceptin trimers linked by EDC could boost direct tumor cell death and overcome resistance to trastuzumab treatment via programmed tumor cell necrosis. 102nd Annual Meeting of the American Association for Cancer Research, 2011.
- Liu D, Yuan G, Hu J Synthesis and photo-induced DNA cleaving activities of conjugates of halophenyl derivative and polyamide containing N-methylimidazoles 83(3):187-193, 2006. PMID: 16403643.
Abstracts
- Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T-cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. 108th American Association of Immunologists (AAI) IMMUNOLOGY, 2025.
- Hu J, Lazar A, Ingram D, Wang W, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. attIL12-T cell therapy destructs cancer-associated fibroblasts and extracellular matrix in heterogenous osteosarcoma xenograft models. 114th American Association for Cancer Research Annual Meeting 2023 83((7_Supplement): 4102), 2023. e-Pub 2023.
- Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Wall FN, Zhang Z, Mahadeo K, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. 105th American Association of Immunologists, IMMUNOLOGY 2022 J Immunol (2022) 208 (1_Supplement): 117.13, 2022.
- Hu J. CRS free T cell therapy: T cell membrane anchored and tumor targeted IL12 (ATTIL12)-T cell therapy eliminates large tumors, overcomes heterogeneity, and avoids adverse effects. 104th American Association of Immunologists (AAI), IMMUNOLOGY 2020 Accepted, 2020.
- Hu J, Xia X, Li S. Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. 110th American Association for Cancer Research Annual Meeting 2019 Cancer Res (2019) 79 (13_Supplement): 1196, 2019.
- Hu J. Combinational Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors. Cancer Immunotherapy: Combinations (C5) 2018, Keystone Symposia, 2018.
- Hu J, Batth I, Bernatchez C, Xia X, Hwu P, Gorlick R, Li S. NKG2D ligand–inducing immune therapy plus NKG2D+CD8+ T cell therapy overcomes chemoresistance in tumors. Society for Immunotherapy of Cancer 2017 Annual Meeting P179, 2017.
- Hu J, Bernatchez C, Xia X, Xu Z, Hwu P, Li S. CXCL9, CXCL10 and IFNγ favor the accumulation of infused T cells in tumors following IL-12 plus doxorubicin treatment. 100th American Association of Immunologists, IMMUNOLOGY 2016 J Immunol (2016) 196 (1_Supplement): 212.1, 2016.
- Hu J, Xia X, Kleinerman ES, Li S. CD8+T cell-mediated tumor-specific induction of the NKG2D ligands to trigger NKG2D-dependent tumor cell death in vivo. 106th American Association for Cancer Research Annual Meeting 75(15_Supplement):4047, 2015. e-Pub 2015.
- Hu J, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 requires the engagement of CD80 and CD28. 105th Annual Meeting of the American Association for Cancer Research Cancer Res (2014) 74 (19_Supplement): 160, 2014.
- Hu J, Zhu S, Kleinerman E, Li S. Co-stimulation of IL-12 gene delivery plus doxorubicin induces NKG2D-dependent CD8+T cell infiltration to tumors and inhibition of tumor progression. 104th Annual Meeting of the American Association for Cancer Research 2013 Cancer Res (2013) 73 (8_Supplement): 4996, 2013.
- Hu J, Zhu S, Xia X, Yokoyama WM, Li S. Regulation of NKG2D expression and NKG2D-positive T cell tumor-specific trafficking by doxorubicin and IL-12 in vivo. 103rd Annual Meeting of the American Association for Cancer Research Cancer Res (2012) 72 (8_Supplement): 404, 2012.
- Hu J, Huang Q, Zhang B, Hughes DPM, Chandra J, Xia X, Li S. Herceptin trimers linked by EDC could boost direct tumor cell death and overcome resistance to trastuzumab treatment via programmed tumor cell necrosis. Cancer Res 71((8_Supplement)):4559, 2011. e-Pub 2011.
Book Chapters
- Hu J, Li S. Electroporation formulation for cell therapy. In: Methods Mol Biol, 55-60, 2014.
- Hu J, Cutrera J, Li S. The impact of non-electrical factors on electrical gene transfer. In: Methods Mol Biol, 47-54, 2014.
Patents
- Shulin Li, Jiemiao Hu, Xueqing Xia. T Cells Expressing Membrane-Anchored IL-12 for the Treatment of Cancer. Patent Number: 1142010.
- FGL2 monoclonal antibodies and their use in treating malignant tumors. Patent Number: 11512141.
- Hu J. FGL2 Monoclonal Antibodies And Their Use In Treating Malignant Tumors. Patent Number: CN110831622B.
Patient Reviews
CV information above last modified March 31, 2026